Could a common diabetes drug help control cystic fibrosis-related diabetes?
NCT ID NCT06149793
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 23 times
Summary
This study tests whether empagliflozin, a diabetes medication, is safe and tolerable for overweight adults with cystic fibrosis-related diabetes (CFRD). Eight participants will receive either the drug or a placebo, then switch after a washout period. The goal is to gather early data to plan a larger trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.